ANGIOIMMUNOBLASTIC LYMPHADENOPATHY (AILD)-TYPE T-CELL LYMPHOMA - PROGNOSTIC IMPACT OF CLINICAL OBSERVATIONS AND LABORATORY FINDINGS AT PRESENTATION

Citation
W. Siegert et al., ANGIOIMMUNOBLASTIC LYMPHADENOPATHY (AILD)-TYPE T-CELL LYMPHOMA - PROGNOSTIC IMPACT OF CLINICAL OBSERVATIONS AND LABORATORY FINDINGS AT PRESENTATION, Annals of oncology, 6(7), 1995, pp. 659-664
Citations number
24
Categorie Soggetti
Oncology
Journal title
ISSN journal
09237534
Volume
6
Issue
7
Year of publication
1995
Pages
659 - 664
Database
ISI
SICI code
0923-7534(1995)6:7<659:AL(TL->2.0.ZU;2-7
Abstract
Background: In order to establish the clinico-pathological properties of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma, we evaluated the type, incidence and prognostic significance of clinical and laboratory symptoms.Patients and methods: Sixty-two consecutive pa tients diagnosed at the Kiel lymph node registry participated in the s tudy. The median patient age was 64 years (range 21-87 years) and the female to male ratio was 1:1.4. Ninety percent of the patients were in stage III and IV and B-symptoms were observed in 68%. At diagnosis pa tients presented with skin rash (49%), pruritus (32%), edema (38%), pl eural effusion (37%), arthritis (18%) and ascites (23%). Furthermore, they exhibited autoimmune phenomena such as cold agglutinines, circula ting immune complexes, a positive Coombs test, smooth muscle antibodie s, rheumatoid factors, immune hemolysis, a paraprotein, antinuclear an tibodies and cryoglobulins. Results: In univariate analysis, survival was significantly related to age (p = 0.032), stage (p = 0.037), B sym ptoms (p = 0.007), rash/pruritus (p = 0.038), edema (p = 0.030), ascit es (p = 0.013), number of clinical symptoms including B symptoms (p = 0.004) and excluding B symptoms (p = 0.017), lactate dehydrogenase (p = 0.007) and hemoglobin (p = 0.020). Conclusions: AILD type T-cell lym phoma characteristically differs from other non-Hodgkin's lymphomas in its clinical signs and laboratory symptoms.